1015 results about "Colitis" patented technology

The invention belongs to the field of new application of medicines, and particularly relates to gastrodia elata polysaccharide and application thereof. The gastrodia elata polysaccharide component GEP-2 is separated from crude gastrodia elata polysaccharide, structural characterization detection is conducted on the GEP-2, the result shows that the gastrodia elata polysaccharide GEP-2 is prepared from, by mass, 89.08% of glucose, 2.40% of galactose, 7.12% of galacturonic acid, 0.86% of arabinose and 0.54% of rhamnose, and the animal experiment result shows that the GEP-2 relieves the symptoms of mouse colitis, relieves weight loss and shortens the colon length; the traditional Chinese medicine composition has the advantages of reducing serum TNF-alpha, IL-1beta and IL-6 proinflammatory cytokine levels, improving the intestinal barrier function, reducing inflammatory cell infiltration, regulating the intestinal flora composition structure of mice and relieving ulcerative colitis.

The invention relates to an intelligent endoscope image evaluation method for ulcerative colitis, and the method comprises the steps: synchronously collecting video streams and three-dimensional point cloud data of a colonic mucosa through an endoscope system equipped with a structured light depth sensor, and constructing a three-dimensional coordinate system based on a colon anatomy trend; based on the three-dimensional point cloud data, constructing a complex topological structure on the surface of the colonic mucosa, and calculating a continuous homology feature set of the lesion area; and based on the persistent homology feature set, constructing a multi-scale graph neural network model of ulcerative colitis and Crohn disease specificity. By implementing the scheme, the structural and topological modeling of the colon mucosa lesion area can be realized, and the morphological characteristic difference between ulcerative colitis and Crohn's disease can be effectively captured. The multi-scale graph neural network fuses macroanatomical segmentation and micropathology features, efficient distinguishing of continuous and jumping lesions is achieved, finally, an intelligent and visual endoscope evaluation report is generated, and the accuracy and real-time performance of auxiliary diagnosis in an operation are improved.

The invention relates to the field of ulcerative colitis, and discloses a multi-parameter monitoring system for evaluating the intestinal barrier function of ulcerative colitis, which is used for realizing the goal of automatically adjusting a treatment scheme according to a monitoring result by constructing a closed-loop feedback treatment system. According to the invention, by designing the nanoprobe of which the surface is modified with a specific binding element and combining with a swallowing capsule endoscopy, real-time imaging and molecular level dynamic tracking of the intestinal barrier are realized, genetically engineered bacteria are constructed to quantify intestinal permeability abnormality and local inflammation level, and an intestinal barrier function damage score and a disease progress prediction result are output; individual monitoring is achieved through transfer learning, ultrasonic elastography, optical coherence tomography, wearable equipment for measuring intestinal electric field impedance spectroscopy and other technologies are adopted, an intestinal wall mechanics-electrophysiology composite parameter set is obtained, and the evaluation accuracy is improved.

The invention relates to a bifidobacterium animalis subsp. Lactis B7 as well as a composition and application thereof, and belongs to the technical field of microorganisms, the bifidobacterium animalis subsp. Lactis B7 is preserved in the China Center for Type Culture Collection on April 19, 2024, and the preservation number is CCTCC NO: M2024734. The bifidobacterium animalis subsp. Lactis B7 is named as Bifidobacterium animalis subsp. Lactis B7, the composition is named as Bifidobacterium animalis subsp. Lactis B7, and the composition is named as Bifidobacterium animalis subsp. Lactis B7. The invention also discloses application of the B7 fermentation composition in preparation of medicines for preventing and treating ulcerative colitis, constipation and constipation-type ulcerative colitis. According to the bifidobacterium animalis subsp. Lactis B7, high-yield short-chain fatty acid and indolepropionic acid are achieved, sulforaphane is generated through glucoraphanin, intestinal tract movement is improved, ulcerative colitis or inflammatory bowel disease activity index DAI and weight loss caused by the disease activity index DAI are effectively relieved, mouse colon injury is remarkably relieved, and mucosa layers are protected; the effects of resisting inflammation, inhibiting pathogenic bacteria and improving the intestinal barrier function are achieved.

The invention discloses a carrier-free nano-particle with pH / ROS dual response as well as a preparation method and application of the carrier-free nano-particle. The preparation method comprises the following steps: enabling quinolizidine alkaloid and flavonol to be subjected to self-assembly, so as to prepare quinolizidine alkaloid-flavonol carrier-free nano particles; modifying the quinolizidine alkaloid-flavonol carrier-free nano particles by adopting a phenylboronic acid-hyaluronic acid conjugate, so as to prepare nano particles modified by the phenylboronic acid-hyaluronic acid conjugate; and coating the surfaces of the nano-particles modified by the phenylboronic acid-hyaluronic acid conjugate with a pH sensitive polymer to prepare the pH / ROS dual-response carrier-free nano-particles. The sophocarpidine-kaempferol carrier-free nanoparticles with pH / ROS dual response, prepared by the invention, have the advantages of good targeting property, high biocompatibility, small toxicity and adverse reaction and the like, meanwhile, the nanoparticles have a good anti-inflammatory effect, and a new choice is provided for the treatment of ulcerative colitis.

The invention relates to the technical field of biological medicine, in particular to a lactobacillus-sourced extracellular vesicle and application of the lactobacillus-sourced extracellular vesicle in prevention and treatment of necrotizing enterocolitis, the extracellular vesicle is prepared from lactobacillus, the lactobacillus is Lactobacillus rhamnosus GG, the strain is purchased in the American Center for Type Culture Collection, and the preservation number is ATCC 53103. The preparation method of the extracellular vesicles comprises the following steps: carrying out ultracentrifugation on a lactobacillus culture solution, removing thalli, then collecting supernate, carrying out primary microfiltration, taking micro-filtrate, carrying out differential centrifugation, resuspending precipitates by using PBS, then carrying out secondary microfiltration, collecting the micro-filtrate, carrying out density gradient centrifugation, and collecting a 30-45% interface vesicle layer. The invention discloses a synergistic effect mode between intestinal symbiotic flora and intestinal epithelial cell metabolic molecules for the first time, and the discovery is expected to construct a brand-new mechanism normal form for regulating the host intestinal barrier function by flora.

The invention discloses an oral monoclonal antibody micro-coated nanopolysaccharide microsphere preparation for targeted therapy of inflammatory bowel diseases and a preparation method thereof. According to the method, oxidized mannan and an anti-TNF-alpha monoclonal antibody are mixed and cross-linked by a cross-linking agent containing a diselenide bond to form the drug-loaded nanoparticles. Mixing the drug-loaded nanoparticles with pectin, dropwise adding the mixture into a calcium chloride solution through an electrostatic spinning device, and carrying out ionic crosslinking to obtain the oral monoclonal antibody micro-coated nano polysaccharide microsphere preparation with the particle size range of 180-200 microns. The drug-loaded polysaccharide microsphere delivers the wrapped drug-loaded nanoparticles to a colitis disease part through electrostatic interaction. The drug-loaded nanoparticles are targeted to macrophages, release of the monoclonal antibody is accelerated under the triggering of high-concentration active oxygen at an inflammation part, and the oral stability and the treatment effect of the monoclonal antibody drug are improved. The polysaccharide is used as a monoclonal antibody targeted delivery carrier, raw materials are cheap and easy to obtain, the preparation process is simple and convenient, reaction conditions are mild, and application and development are easy.

IL-23 binding proteins (e.g., antibodies) and methods of use, including methods of treating inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease) comprising administering IL-23 binding proteins.

The present invention discloses a black chicken liver hydrolyzed peptide that can be used to improve ulcerative colitis, and its preparation method and application, which belong to the field of biomedicine technology. The preparation method of the black chicken liver hydrolyzed peptide comprises the following steps: making black chicken liver into minced meat and mixing it with water, heating the obtained liquid material, adding alkaline protease for enzymatic hydrolysis, inactivating the enzyme and collecting the supernatant by centrifugation, and freeze-drying to obtain the black chicken liver hydrolyzed peptide. The present invention adopts formaldehyde titration to detect the degree of hydrolysis, adopts SDS-PAGE electrophoresis and Tricine-SDS-PAGE electrophoresis to detect the molecular weight, performs sequence analysis by LC-MS / MS, uses a database to predict the biological function of peptide segments, detects the antioxidant and blood pressure lowering ability of black chicken liver peptide by in vitro experiments, and detects the effect of black chicken liver peptide in improving colitis by mouse experiments. The results show that the black chicken liver peptide prepared by the present invention has the advantages of antioxidant, blood pressure lowering and improvement of ulcerative colitis.

The invention provides an Akkermann Amuc1100 protein mutant as well as a preparation method and application thereof, wild Akkermann Amuc1100 protein is subjected to mutation modification through a molecular biological technical means, and the bioactivity of the Amuc1100 protein mutant subjected to molecular modification is obviously improved compared with that of the wild protein; compared with a wild type Amuc1100 protein, the wild type Amuc1100 protein has a better effect when being applied to the aspects of regulating intestinal immunity, relieving acute pancreatitis, promoting browning of white adipose cells, inhibiting obesity, relieving ulcerative colitis and the like, and a very good application prospect is provided for developing bioactive medicines with higher efficiency.

The invention belongs to the technical field of nano material synthesis, and particularly relates to baicalein-copper nano microgel as well as a preparation method and application thereof. According to the invention, copper ions and baicalein are coordinated to form nanowires, and the nanowires are coated with hyaluronic acid (HA) to prepare the nano microgel. The method is carried out at normal temperature, is simple in process and high in yield, and does not need toxic solvents; the obtained microgel has high stability (gastric acid resistance), targeted delivery (CD44 receptor mediation) and multiple biological activities (oxidation resistance and inflammation resistance). Animal experiments show that the pharmaceutical composition can significantly relieve ulcerative colitis, the dosage is as low as 5 mg / kg, the pharmaceutical composition is non-toxic, and a new strategy is provided for treatment of inflammatory diseases.

The invention discloses a capsule medicament for endoscopic treatment of ulcerative colitis and a preparation method thereof, and belongs to the technical field of biological medicine, the capsule medicament is composed of a capsule matrix and a drug matrix; by adopting a dual control mechanism of an enteric layer coating and a pH response layer coating, accurate release of a medicine at a colon diseased region is ensured, medicine waste of the stomach and the small intestine is reduced, the medicine concentration at a focus is improved, mesalazine or budesonide is combined with the composite composition for treatment, inflammatory response is rapidly inhibited, acute symptoms are controlled, and the curative effect is good. A multi-mechanism synergistic treatment mode is adopted, the anti-inflammatory and repairing effects are enhanced, the clinical remission rate and the mucous membrane healing rate are remarkably improved, the pH response layer is dissolved in a colon alkaline environment, and the MMP-9 peptide cross-linking agent is subjected to enzymolysis at an inflammation part, so that the medicine is continuously released at a focus, the administration frequency is reduced, the compliance of a patient is improved, and the curative effect is good. In addition, the spherical gel particles in the medicament can prevent the medicament from being disintegrated too early in the intestinal tract, and the long-acting effect can be maintained.

The invention discloses an anus medicine applying and applying device suitable for local treatment of ulcerative colitis, relates to the field of medical instruments, and solves the problem that an existing anus medicine applying device is difficult to operate. The anus medicine applying and applying device comprises a device shell and an injection tube installed at the end of the device shell, and a holding cylinder is arranged on the outer side of the device shell; a rubber piston is mounted on the inner side of the device shell in a sliding manner; the dosing mechanism is used for improving the medicine applying convenience of the injection tube, and the dosing mechanism is installed between the device shell and the holding cylinder; through the administration mechanism, a pushing rubber piston can be pushed to be arranged on the outer side of the device shell, so that an L-shaped structure is formed between the device shell and the holding cylinder, a patient can conveniently insert an injector into the anus with a single hand, the device is convenient for patients with more body types to use, the problem that a traditional medicine applying device is difficult to operate is solved, the pain of the patient in medicine applying is relieved, and the patient experience is improved. Therefore, the convenience of applying medicine to the anus is improved.

The invention relates to betulinic acid type saponin derivatives as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The structural general formula of the betulinic acid type saponin derivative is # imgabs0, R1 is selected from hydroxyl or-O-G, and G is monosaccharide; r2 is selected from dopamine, 5-aminovaleric acid, 4-aminobutyric acid or 3-aminopropionic acid and the like and salts thereof. The betulinic acid type saponin derivative does not show obvious cytotoxicity to THP-1 macrophages, and can obviously reduce the release of IL-6 and IL-1beta in the THP-1 macrophages induced by LPS (lipopolysaccharide). Compared with betulinic acid and positive control medicine mesalazine, the pharmaceutical composition has better anti-inflammatory activity, has the treatment effect of improving diarrhea and hemafecia of mice with colitis remarkably superior to those of betulinic acid and positive control medicine mesalazine, has the treatment effect of dermatitis superior to that of positive control medicine dexamethasone, and does not have obvious toxic or side effects such as weight loss and immunosuppression. Therefore, the betulinic acid type saponin derivative has good in-vivo and in-vitro safety and druggability.

The invention provides assays and methods for analyzing inflammatory disorders of the gastrointestinal (GI) tract. Provided in embodiments of the invention are host transcriptome markers and classifiers amenable for assessing and monitoring the existence, severity and location of inflammation associated with inflammatory bowel disease (IBD), Crohn's disease (CD) and Ulcerative colitis (UC). Further provided are improved protocols for processing and analyzing fecal samples, providing superior non-invasive means for evaluating GI inflammation.

According to the borborygmus recognition method and device, the electronic equipment and the storage medium, the borborygmus signal is acquired, the signal is recognized based on the preset borborygmus recognition model, the borborygmus characteristics can be efficiently and accurately analyzed, and therefore a scientific basis is provided for evaluation of the activity range and the lesion range of colitis diseases. According to the method, the diagnostic efficiency and accuracy are improved, through non-invasive borborygmus signal analysis, complexity of traditional endoscopy and discomfort of a patient are avoided, and meanwhile the diagnostic accuracy is improved; and secondly, dynamic monitoring of disease activity is realized, the activity and lesion range of colitis can be evaluated in real time by continuously collecting and identifying borborygmus signals, and dynamic illness state data support is provided for doctors.

The invention relates to an oral probiotic-mediated drug delivery system as well as a preparation method and application thereof. The preparation method comprises the following steps: preparing polydopamine nano coating bacteria from probiotics and dopamine; a process of preparing drug-loaded polydopamine nanoparticles from dopamine and a functional drug; and a process of preparing a drug delivery system from the polydopamine nano-coated bacteria and the drug-loaded polydopamine nanoparticles, the drug delivery system prepared by the method is applied to preparation of drugs for preventing or treating tumors, colitis, diarrhea, constipation, diabetes mellitus and obesity. The preparation method disclosed by the invention has the advantages of simple preparation, mildness and stable performance, the prepared drug delivery system adopts a polydopamine single bacterium coating method to encapsulate the probiotics, and the drug-loaded nanoparticles are loaded on the surface of the probiotics, so that the effects of efficient drug delivery and micro-ecological regulation functions are achieved, and a better treatment effect is achieved.

The invention discloses an establishment method and application of a damp-heat intestine accumulation type ulcerative colitis animal model, and belongs to the field of animal models.The establishment method comprises the steps that S1, high-fat feed treatment is conducted, specifically, experimental animals freely eat high-fat feed for 6-10 weeks from the first day; s2, DSS treatment: feeding 1.5% (w / v) DSS solution to the experimental animal for 2 weeks; and S3, observing the damp-heat syndrome type and ulcerative colitis related indications of the experimental animals, and selecting the experimental animals meeting the scoring standard, thereby establishing the ulcerative colitis mouse model. Aiming at the situation that most patients induce ulcerative colitis due to excess energy due to the change of dietary structures and lifestyles at present, the invention constructs and evaluates the damp-heat accumulation type ulcerative colitis mouse model by inducing internal dampness by a direct pathogenesis (high fat diet), which is closer to the actual situation of clinical patients. Therefore, a model and reference are provided for research and treatment of pathology of the damp-heat accumulation type ulcerative colitis and pharmacological mechanisms of traditional Chinese medicines.

The invention belongs to the field of microorganisms, and relates to lactobacillus paracasei. In particular discloses a lactobacillus paracasei strain HNGD-AL1, the taxonomic name is Lactobacillus paracasei, the lactobacillus paracasei strain HNGD-AL1 is preserved in China Center for Type Culture Collection on February 27, 2025, the preservation number is CCTCC M 2025303, and the preservation address is No. 299 on eight road in Wuchang District, Wuhan, Hubei. The method for degrading the sulfur-containing amino acid by adopting the lactobacillus paracasei is found for the first time, the effect of degrading 53.39% of the sulfur-containing amino acid can be achieved by culturing the probiotics in a fermentation culture medium for 24 hours, and the probiotics can be colonized in intestinal tracts and play a role in degrading the sulfur-containing amino acid in intestinal contents; the content of metabolite hydrogen sulfide of sulfur-containing amino acid in the intestinal tract is reduced by 60.92%, intestinal tract tissue damage, permeability and inflammatory response are reduced, and the purpose of improving ulcerative colitis is achieved. The preparation method has a wide application prospect in the aspects of preparation of low-sulfur-content amino acid foods and probiotic preparations for improving colitis.

The invention discloses a composition containing probiotics and fusion polypeptide and application of the composition in treatment of intestinal inflammatory diseases. The composition is prepared from lactobacillus plantarum (Lactobacillus plantarum CCFM8661) and a functional fusion polypeptide, wherein the amino acid sequence of the fusion polypeptide is as shown in SEQ ID NO. 1. The invention also discloses a preparation method of the composition. The fusion polypeptide can be used for directly inhibiting the growth of pathogenic bacteria and neutralizing toxins by enhancing the intestinal colonization capability of probiotics, so that the triple synergistic effect of bacteriostasis, repair and immunoregulation is realized. Experiments show that the composition significantly reduces the disease activity index in a DSS-induced mouse colitis model, recovers the colon length, and inhibits serum inflammatory factors IL-6 and TNF-alpha. In addition, the survival rate of the freeze-dried microcapsule preparation in simulated gastric juice is gt; the colon targeted release characteristic is realized. The invention provides an efficient and stable new treatment strategy for intestinal inflammatory diseases.

The invention belongs to the field of compositions, and particularly relates to an anti-colitis composition and application, the anti-colitis composition comprises bacillus natto JLNA2301 bacterial liquid and ginseng water-soluble dietary fiber; the preservation number of the bacillus natto JLNA2301 is CGMCC (China General Microbiological Culture Collection Center) No. 27770; the volume mass ratio of the bacillus natto JLNA2301 bacterial liquid to the ginseng water-soluble dietary fibers in the composition is (8-10) mL: (0.25-1) g, and the viable count of the bacillus natto JLNA2301 bacterial liquid is 1 * 10 < 8 >-1 * 10 < 10 > CFU / mL; the composition can be used for preventing and treating colon shortening and bleeding caused by ulcerative colitis, repairing intestinal barrier protein and inhibiting a TLR4 / NF-kappa B inflammation pathway; the intestinal flora structure is regulated in a prevention period and a treatment period.

Disclosed herein in some embodiments are methods, compositions, and systems for distinguishing between ulcerative colitis (UC), Crohn's disease (CD) and other Inflammatory Bowel Disorders (IBD) by sequencing cell free nucleic acids. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether UC, CD, or other IBD are asymptomatic, in remission, or active. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether an active form of UC, CD, or other IBD is mild, moderate, or severe.

The invention relates to a system for evaluating the severity of an ulcerative colitis endoscope, and belongs to the technical field of medical systems. The system comprises a data acquisition module, a label calibration module, an ulcerative colitis endoscope severity evaluation model construction module, an ulcerative colitis endoscope severity evaluation model training module, an ulcerative colitis endoscope severity evaluation module and a second data acquisition module. A histological biopsy scoring and processing module; and a data processing and control module. The system provided by the invention can objectively evaluate the endoscopic disease activity of ulcerative colitis in real time and predict histological alleviation, can more accurately guide the formulation of a clinical treatment scheme, and is easy to popularize and apply.

The invention relates to the technical field of biological medicine, in particular to an ulcerative colitis disease clearance evaluation molecular marker and application thereof. By detecting the expression level of the HMGCS2 gene in a sample, the ulcerative colitis disease clearance state and disease activity period can be evaluated, and the method is used for curative effect monitoring, recurrence prediction and individualized treatment strategy formulation of ulcerative colitis and has important clinical application value and market prospect.

The invention discloses an insoluble dietary fiber-EGCG (epigallocatechin gallate) compound as well as a preparation method and application thereof, and belongs to the field of food processing. The preparation method of the insoluble dietary fiber-EGCG compound comprises the following steps: dispersing insoluble dietary fibers in a phosphate buffer solution, fully expanding, uniformly mixing with an EGCG solution dissolved in the phosphate buffer solution, standing at room temperature for a period of time, centrifuging, taking precipitate, and drying to obtain the insoluble dietary fiber-EGCG compound. The insoluble dietary fiber-EGCG compound disclosed by the invention has the advantages that the intestinal inflammation in a mouse colitis model is obviously relieved, and the effect is far better than that of independently using HPSIDF or EGCG; and the HPSIDF-EGCG compound can synergistically regulate and control intestinal flora-immune axis and improve the intestinal barrier function, has mild adsorption reaction conditions, is suitable for industrial production, and is expected to be developed into a product with high additional value.

A Bifidobacterium longum subsp. longum dipro-017. The Bifidobacterium longum subsp. longum dipro-017 used has the ability to metabolize tryptophan to produce indole-3-lactic acid, can inhibit the pathogenic bacteria Salmonella Typhimurium, Staphylococcus aureus, and Escherichia coli, and can effectively mitigate weight loss caused by ulcerative colitis, improve a DAI score, improve colon length, mitigate the content of lipopolysaccharide (LPS) in blood, and increase the level of anti-inflammatory cytokine IL-10, as well as mitigate the content of bone metabolism indicators tartrate-resistant acid phosphatase (TRAP) and N-terminal propeptide of type I procollagen (PINP) in blood.

The invention provides a preparation method and application of an intestinal adhesion delivery system based on pea 2S albumin. The intestinal adhesion delivery system is a protein-polyphenol compound generated by covalent binding of quinone obtained by oxidizing polyphenol through periodate resin and pea 2S albumin. According to the intestinal adhesion delivery system, cysteine-rich pea 2S albumin is used as a delivery carrier, polyphenol bioactive substances are loaded on the cysteine-rich pea 2S albumin, release of functional components in the digestion process is effectively delayed, and the gastrointestinal stability is improved. The composition is applied to the fields of inflammatory bowel diseases and intestinal infection, can target the diseased region of colitis, and effectively relieves the symptoms of colitis by enhancing the barrier function of intestinal mucosa, regulating intestinal flora and inhibiting inflammatory response. The intestinal adhesion delivery system can also deliver other bioactive substances, is applied to the fields of biological science, functional food and the like, and has good development potential.

The invention provides preparation and application of a cyclodextrin covalent skeleton with active oxygen sensitivity. Specifically, the invention designs a cyclodextrin covalent skeleton bonded by thioketal, and aims to construct an intelligent drug delivery system with active oxygen response and removal. The cyclodextrin covalent skeleton disclosed by the invention can realize active oxygen responsive disintegration in an active oxygen environment, can effectively remove the active oxygen level, has good biological safety and inflammation targeting property, and can enrich anti-inflammatory drugs at colon focus parts to relieve the development and deterioration of colitis diseases.

The invention relates to a pterostilbene compound, a pharmaceutical composition and application of the pterostilbene compound in preparation of anti-inflammatory drugs. The compound shown in the formula (I) or the pharmaceutically acceptable salt thereof provided by the invention has relatively high stability and high bioavailability, can effectively improve symptoms such as colon shortening, diarrhea, hematochezia and weight loss caused by DSS-induced mouse colitis, has a remarkable inhibition effect on intestinal inflammation, and can be used for preparing anti-inflammatory drugs. # imgabs0 #

The invention belongs to the field of biological medicines, and particularly discloses application of uridine in preparation of medicines for preventing and treating ulcerative colitis, including application of uridine in preparation of medicines for preventing and treating ulcerative colitis in acute stage, application of uridine in preparation of medicines for preventing and treating ulcerative colitis in remission stage and the like. Uridine can improve the symptoms of DSS-induced acute experimental colitis model mice, has a good treatment effect, and improves the weight of the model mice; experimental results indicate that a high-dose group of uridine has a good treatment effect, the mechanism and specificity of uridine up-regulate expression and activity of colon local SIRT1 protein, further inhibit phosphorylation activation of an NF-kappa B signal channel, regulate secretion of inflammatory factors and expression of tight junction protein, repair intestinal mucosal barrier while moderately regulating immunity, and improve the immunity of a human body. The systemic inflammatory response is effectively relieved.